Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer
-
Published:2024-08
Issue:
Volume:597
Page:217011
-
ISSN:0304-3835
-
Container-title:Cancer Letters
-
language:en
-
Short-container-title:Cancer Letters
Author:
Oluwalana DamilolaORCID,
Adeleye Kelli L.,
Krutilina Raisa I.ORCID,
Chen Hao,
Playa Hilaire,
Deng ShanshanORCID,
Parke Deanna N.ORCID,
Abernathy John,
Middleton LeonaORCID,
Cullom Alexandra,
Thalluri Bhargavi,
Ma DejianORCID,
Meibohm BerndORCID,
Miller Duane D.,
Seagroves Tiffany N.,
Li WeiORCID
Reference51 articles.
1. Cancer statistics, 2023;Siegel;CA A Cancer J. Clin.,2023
2. Molecular portraits of human breast tumours;Perou;Nature,2000
3. Breast cancer;Harbeck;Nat. Rev. Dis. Prim.,2019
4. National Comprehensive Cancer Network Guidelines for Patients - Metastatic Breast Cancer,2022
5. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer;Bardia;N. Engl. J. Med.,2019